Amrita Pati
Executive Director of Computational Biology, Precision Medicine, Amgen
Seminars
Wednesday 4th February 2026
Panel Discussion: Bridging the Gap from Innovation to Access by Aligning Standardization, Policy & Reimbursement for Liquid Biopsy
12:30 pm
- Uncovering how inconsistent definitions, metrics, and data standards are hindering payer confidence and policy support for liquid biopsy
- Exploring the role of pre-competitive collaboration in driving standardization to unlock broader reimbursement and clinical adoption
- Identifying immediate policy actions and evidence needs to align stakeholders and accelerate access to serial testing and early detection
Wednesday 4th February 2026
Liquid Biopsy Across the Drug Lifecycle: Discovery, Differentiation & Adoption
5:40 pm
- Showing how Amgen leverages ctDNA and other modalities across discovery, clinical development, and commercialization to accelerate differentiation, regulatory approvals, and market adoption
- Highlighting case studies where ctDNA and liquid biopsy analyses informed dose selection, early efficacy readouts, and patient stratification, directly supporting faster decisionmaking and clinical success
- Discussing how Amgen generates the biomarker evidence base needed for regulators, payers, and clinicians to embrace liquid biopsy as a standard tool in advancing precision medicine
Wednesday 4th February 2026
Driving Clinical Validation to Enhance Decision-Making & Accelerate Diagnostic Approval – Chaired by
